PHILLIP YEOH

Mr. PHILLIP YEOH


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2022 in International Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
PYPHILLIP YEOH
PHILLIP YEOH
Andrew A. DwyerAndrew A. Dwyer
Andrew A. Dwyer
EAElla Anghel
Ella Anghel
PBPierre M. Bouloux
Pierre M. Bouloux
BKBernard Khoo
Bernard Khoo
AGAshley B Grossman
Ashley B Grossman
Objective. The insulin tolerance test (ITT) is the gold standard endocrine test used to assess the integrity of the growth hormone (GH) and cortisol axes. The ITT has potential risks, and severe hypoglycaemia may necessitate intravenous glucose rescue. There is no clear consensus as to the optimal insulin dose for the ITT. Therefore, we sought to compare the standard dose (0.15 U/kg) and a low-dose ITT (0.1 U/kg). Design. Single-centre audit of ITT data (2012–2021). Patients and Measurements. Patients who underwent an ITT to assess possible GH deficiency/adrenal insufficiency were included. Glucose, GH, and cortisol were measured at baseline and 30, 45, 60, 90, and 120 minutes following I.V. insulin bolus (0.15 U/kg or 0.10 U/kg). Results. Of the ITTs performed, only 3/177 (1.7%) did not achieve adequate hypoglycaemia (≤2.2 mmol/L) with a single insulin dose. In total, 174 patients (43.5 ± 12.1 yrs, mean ± standard deviation) were included for analysis (0.15 U/kg: n = 113, 0.10 U/kg: n = 61). All 174 subjects had adequate hypoglycaemia regardless of baseline fasting blood glucose level or insulin dose. Neither nadir glucose nor glucose delta (i.e., baseline minus nadir) differed between insulin doses. Trends in both cortisol and GH responses over time were similar between groups, and a greater proportion of patients receiving the standard dose had an adequate cortisol response (77/106 (72.6%) vs. 32/60 (53.3%), ). The rates of glucose rescue did not differ in a subset of 79 patients, with on-demand glucose rescue in 4/35 (11%) for the standard dose and 2/44 (5%) for the low dose ( ). Conclusions. Our results suggest that the low-dose ITT produces comparable glucose, cortisol, and GH responses to the higher dose. Given the risks associated with hypoglycaemia, the low dose appears to be preferable to the standard dose ITT in most circumstances.

6 June 2022 in Endocrinology, Diabetes & Metabolism
Verified
Journal Article
Open access
PYPHILLIP YEOH
PHILLIP YEOH
WCWladyslawa Czuber‐Dochan
Wladyslawa Czuber‐Dochan
SASimon Aylwin
Simon Aylwin
JSJackie Sturt
Jackie Sturt
Introduction: Adrenocortical carcinoma (ACC) is a rare cancer with an annual incidence of 0.7–2 cases per million population and 5‐year survival of 31.2%. Adrenal insufficiency (AI) is a common and life shortening complication of ACC, and little is understood about how it impacts on patients' experience.Objective: To understand patients' lived experience of the condition, its treatment, care process, impact of AI on ACC wellbeing, self‐care needs and support.Methods: Systematic review of MEDLINE, EMBASES, CINAHL, PsycINFO and Open Grey for studies published until February 2021. All research designs were included. The findings underwent a thematic analysis and narrative synthesis. Studies quality was assessed using mixed method assessment tools.Results: A total of 2837 citations were identified; 15 titles with cohort, cross‐sectional, case series and case report study designs met the inclusion criteria involving 479 participants with adrenal insufficiency secondary to adrenocortical carcinoma (AI/ACC). Quantitative research identified impacts of disease and treatment on survivorship, the burden of living with AI/ACC, toxicity of therapies, supporting self‐care and AI management. These impact factors included adjuvant therapies involved and their toxicities, caregivers/family supports, healthcare and structure support in place, specialist skill and knowledge provided by healthcare professional on ACC management. No qualitative patient experiences evidence was identified.Conclusion: ACC appears to have high impact on patients' wellbeing including the challenges with self‐care and managing AI. Evidence is needed to understand patient experience from a qualitative perspective.

8 July 2026 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
PYPHILLIP YEOH
PHILLIP YEOH
JSJackie Sturt
Jackie Sturt
WCWladyslawa Czuber-Dochan
Wladyslawa Czuber-Dochan
Background and objective: Adrenocortical carcinoma (ACC) is a rare and aggressive malignancy of the adrenal glands, characterised by high recurrence rates and poor survival outcomes. Living with ACC is associated with significant uncertainty and psychological burden. This study aimed to explore the experiences, impacts, and perceptions of people living with ACC to inform the development of comprehensive, person-centred care. Methods: A qualitative study underpinned by Van Manen’s hermeneutic phenomenological methodology was undertaken. Semi-structured interviews were conducted, informed by Mullan’s concept of survivorship, Bowen’s Family System Theory, and the concept of resilienc e . These frameworks guided both data collection and analysis. Findings: Twenty-one participants (12 women, 9 men; mean age 50, range 28–74) from the USA, Canada, UK, Europe, Nigeria, and Australia took part in interviews totalling 19 hours and 34 minutes. Five themes and 11 subthemes emerged. Living with ACC was described as an existential challenge, as participants navigated the reality of limited survival alongside demanding, life-prolonging treatments. The pursuit of survival was likened to a rollercoaster, requiring sustained support and continuous adaptation. For some, these challenges became overwhelming and led to thoughts of suicide. Participants highlighted a strong need for hope, understanding, and compassionate, ongoing care to help them cope, adapt, and rebuild their lives. Conclusion: ACC is a complex and life-altering condition that requires careful balancing of treatment burden with quality-of-life considerations. Current healthcare systems do not adequately meet the needs of this population. Future research should focus on developing and evaluating interventions to better support individuals living with ACC and mitigate the psychological and practical impacts of the disease.